93.48
price up icon0.97%   0.89
 
loading
Incyte Corp stock is traded at $93.48, with a volume of 1.36M. It is up +0.97% in the last 24 hours and up +10.23% over the past month. Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$92.59
Open:
$92.7
24h Volume:
1.36M
Relative Volume:
0.72
Market Cap:
$18.25B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
21.25
EPS:
4.3988
Net Cash Flow:
$945.58M
1W Performance:
+2.42%
1M Performance:
+10.23%
6M Performance:
+49.20%
1Y Performance:
+26.13%
1-Day Range:
Value
$92.06
$95.10
1-Week Range:
Value
$84.02
$95.10
52-Week Range:
Value
$53.56
$95.10

Incyte Corp Stock (INCY) Company Profile

Name
Name
Incyte Corp
Name
Phone
(302) 498-6700
Name
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Employee
2,617
Name
Twitter
@Incyte
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
INCY's Discussions on Twitter

Compare INCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INCY
Incyte Corp
93.46 18.18B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
425.79 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
650.00 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
458.46 58.93B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
813.54 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.31 41.29B 398.11M -1.03B -868.57M -5.7032

Incyte Corp Stock (INCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-08-25 Downgrade Oppenheimer Outperform → Perform
Aug-06-25 Upgrade Wells Fargo Equal Weight → Overweight
Aug-01-25 Initiated Barclays Overweight
Jun-16-25 Upgrade Stifel Hold → Buy
Mar-18-25 Downgrade Guggenheim Buy → Neutral
Mar-18-25 Downgrade William Blair Outperform → Mkt Perform
Dec-17-24 Initiated UBS Neutral
Oct-29-24 Upgrade BofA Securities Neutral → Buy
Oct-01-24 Initiated Wolfe Research Outperform
Sep-18-24 Downgrade Truist Buy → Hold
Jul-02-24 Downgrade BMO Capital Markets Market Perform → Underperform
May-23-24 Initiated Deutsche Bank Hold
Apr-23-24 Initiated Cantor Fitzgerald Neutral
Feb-23-24 Initiated Jefferies Buy
Feb-14-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-23 Upgrade Leerink Partners Market Perform → Outperform
Dec-04-23 Upgrade Guggenheim Neutral → Buy
Nov-21-23 Downgrade Goldman Buy → Neutral
Jul-25-23 Initiated Citigroup Buy
May-04-23 Downgrade BofA Securities Buy → Neutral
Apr-10-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-24-23 Upgrade SVB Securities Underperform → Market Perform
Jan-31-23 Initiated Piper Sandler Overweight
Aug-03-22 Downgrade Evercore ISI Outperform → In-line
Aug-03-22 Downgrade Guggenheim Buy → Neutral
Jul-28-22 Initiated Wells Fargo Equal Weight
Feb-09-22 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-18-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-19-21 Initiated BMO Capital Markets Market Perform
Jul-20-21 Upgrade The Benchmark Company Hold → Buy
Feb-10-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-07-21 Initiated Truist Buy
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jun-16-20 Initiated The Benchmark Company Hold
May-06-20 Downgrade JP Morgan Overweight → Neutral
Apr-29-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-24-20 Resumed William Blair Outperform
Mar-13-20 Upgrade BofA/Merrill Neutral → Buy
Feb-04-20 Resumed BofA/Merrill Neutral
Jan-03-20 Reiterated BMO Capital Markets Market Perform
Jan-03-20 Downgrade Mizuho Buy → Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Oct-03-19 Initiated Mizuho Buy
Sep-12-19 Initiated BMO Capital Markets Market Perform
Sep-05-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Sep-05-19 Resumed Morgan Stanley Equal-Weight
Sep-05-19 Upgrade Oppenheimer Perform → Outperform
May-21-19 Initiated Credit Suisse Neutral
May-03-19 Downgrade Barclays Overweight → Equal Weight
Apr-11-19 Initiated Stifel Hold
Apr-03-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-24-19 Upgrade William Blair Mkt Perform → Outperform
View All

Incyte Corp Stock (INCY) Latest News

pulisher
05:47 AM

Key metrics from Incyte Corporation’s quarterly data2025 Big Picture & Short-Term High Return Strategies - newser.com

05:47 AM
pulisher
03:56 AM

Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com

03:56 AM
pulisher
12:24 PM

Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus

12:24 PM
pulisher
12:11 PM

Can Incyte Corporation stock hit record highs againWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com

12:11 PM
pulisher
Oct 30, 2025

Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo! Finance UK

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte's (INCY) Hold Rating Reiterated at Truist Financial - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte (INCY) Gains Exclusive Distribution Rights for Tafasitamab in Latin America - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Transcend Capital Advisors LLC Makes New $437,000 Investment in Incyte Corporation $INCY - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Multi asset correlation models including Incyte CorporationMarket Risk Report & Fast Gain Stock Trading Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Will Incyte Corporation (ICY) stock return to pre crash levels2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Can Incyte Corporation stock deliver sustainable ROELayoff News & Safe Entry Point Alerts - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 29, 2025
pulisher
Oct 29, 2025

RBC Capital Raises Incyte (INCY) Price Target to $84 | INCY Stoc - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte (INCY) Rating Reiterated and Price Target Raised by Truis - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Wells Fargo Raises Incyte (INCY) Price Target to $97.00 | INCY S - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte (INCY): Barclays Raises Price Target to $101 with Overwei - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte Corporation $INCY Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

How Incyte Corporation stock responds to policy changes2025 Valuation Update & Safe Capital Growth Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 29, 2025

How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 28, 2025

Incyte: Q3 Earnings Snapshot - Stamford Advocate

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (NASDAQ:INCY) Hits New 12-Month HighWhat's Next? - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Walloped Third-Quarter Profit Views. Why Shares Fell. - Investor's Business Daily

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Benzinga

Oct 28, 2025
pulisher
Oct 28, 2025

1 Growth Stock Under $100 to Buy Before It Soars - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) - Insider Monkey

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Sees Strong Growth with Key Products and Raises Gu - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Why Incyte (INCY) Stock Is Trading Lower Today - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte stock price target raised to $109 by BofA on strong Jakafi sales - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Raises Sales Targets But Investors Aren’t Cheering - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) PT Raised to $109 at BofA Securities - StreetInsider

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Q3 2025 slides: Revenue jumps 20% as product portfolio expands - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings call transcript: Incyte Q3 2025 beats forecasts, stock surges - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Boosts 2025 Revenue Forecast on Strong Product Dem - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corporation (INCY) Q3 FY2025 earnings call transcript - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates - BioSpace

Oct 28, 2025
pulisher
Oct 28, 2025

Why Incyte Corporation (ICY) stock stays resilientWeekly Market Report & Growth Focused Stock Pick Reports - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corp (INCY) Q3 2025 Earnings: EPS of $2.11 Beats Estimates, Revenue Surges to $1.37 Billion - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte shares rise as third quarter results beat expectations, guidance raised By Investing.com - Investing.com South Africa

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte shares rise as third quarter results beat expectations, guidance raised - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte releases new data from Phase IIIb trial of Opzelura in dermatitis - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte earnings beat by $0.67, revenue topped estimates - Investing.com

Oct 28, 2025

Incyte Corp Stock (INCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$28.53
price down icon 0.51%
$37.45
price up icon 1.33%
$103.54
price down icon 0.95%
biotechnology ONC
$311.87
price up icon 0.97%
$189.00
price down icon 2.75%
Cap:     |  Volume (24h):